Silvio Bicciato

Prof. Silvio Bicciato

orcid

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 June 2011 in Nature
Verified
Journal Article
Closed access
SDSirio Dupont
Sirio Dupont
LMLeonardo Morsut
Leonardo Morsut
MAMariaceleste Aragona
Mariaceleste Aragona
EEElena Enzo
Elena Enzo
SGStefano Giulitti
Stefano Giulitti
SPStefano Piccolo
Stefano Piccolo

1 November 2011 in Cell
Verified
Journal Article
Closed access
MCMichelangelo Cordenonsi
Michelangelo Cordenonsi
FZFrancesca Zanconato
Francesca Zanconato
LALuca Azzolin
Luca Azzolin
MFMattia Forcato
Mattia Forcato
ARAntonio Rosato
Antonio Rosato
SPStefano Piccolo
Stefano Piccolo

1 July 2014 in Cell
Verified
Journal Article
Closed access
LALuca Azzolin
Luca Azzolin
TPTito Panciera
Tito Panciera
SSSandra Soligo
Sandra Soligo
EEElena Enzo
Elena Enzo
SBSilvio Bicciato
Silvio Bicciato
SPStefano Piccolo
Stefano Piccolo

1 June 2010 in Immunity
Verified
Journal Article
Closed access
IMIlaria Marigo
Ilaria Marigo
EBErika Bosio
Erika Bosio
SSSamantha Solito
Samantha Solito
CMCirce Mesa
Circe Mesa
AFAudry Fernandez
Audry Fernandez
VBVincenzo Bronte
Vincenzo Bronte

1 April 2009 in Cell
Verified
Journal Article
Closed access
MAMaddalena Adorno
Maddalena Adorno
MCMichelangelo Cordenonsi
Michelangelo Cordenonsi
MMMarco Montagner
Marco Montagner
SDSirio Dupont
Sirio Dupont
CWChristine Wong
Christine Wong
SPStefano Piccolo
Stefano Piccolo

2 October 2006 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
GGGiovanna Gallina
Giovanna Gallina
LDLuigi Dolcetti
Luigi Dolcetti
PSPaolo Serafini
Paolo Serafini
CSC. D. Santo
C. D. Santo
IMIlaria Marigo
Ilaria Marigo
VBVincenzo Bronte
Vincenzo Bronte
Active suppression of tumor-specific T lymphocytes can limit the efficacy of immune surveillance and immunotherapy. While tumor-recruited CD11b+ myeloid cells are known mediators of tumor-associated immune dysfunction, the true nature of these suppressive cells and the fine biochemical pathways governing their immunosuppressive activity remain elusive. Here we describe a population of circulating CD11b+IL-4 receptor α+ (CD11b+IL-4Rα+), inflammatory-type monocytes that is elicited by growing tumors and activated by IFN-γ released from T lymphocytes. CD11b+IL-4Rα+ cells produced IL-13 and IFN-γ and integrated the downstream signals of these cytokines to trigger the molecular pathways suppressing antigen-activated CD8+ T lymphocytes. Analogous immunosuppressive circuits were active in CD11b+ cells present within the tumor microenvironment. These suppressor cells challenge the current idea that tumor-conditioned immunosuppressive monocytes/macrophages are alternatively activated. Moreover, our data show how the inflammatory response elicited by tumors had detrimental effects on the adaptive immune system and suggest novel approaches for the treatment of tumor-induced immune dysfunctions.